Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®
「The result that Boehringer Ingelheim』s adalimumab biosimilar candidate delivers the same clinical benefits and safety profile as HUMIRA® is great news for patients and physicians. If approved......
